HealthcareMid capRs 10,464 crRs 8.8 cr traded a day
Close on 10 September 2026
700.90
−1.63%
52-week range70% of the way up
521.75776.30
Market cap
10,464 cr
P/E (TTM)
314.6×
industry 45×
EPS (TTM)
2.23
Revenue YoY
+13.4%
Q1 FY27
Profit YoY
+175.3%
Net margin
2.4%
+1.4pt vs a year ago
Growth trend
+1.9pt
vs last quarter’s YoY
1 month
-4.8%
Below 52w high
10.8%
RSI (14)
43
Daily swing
3.8%
average true range
Volume
1.5×
vs 20-day average
Traded
Rs 9 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
Key metrics
each ranked against every stock scanned tonight
Above the 200-day average
Around the median
+11.4%
One-year return
Around the median
+7.7%
Return on capital employed
n/a
Debt to equity
n/a
Profitable quarters, last four
of the last four reported
3 of 4
Cash conversion
cash from operations against reported profit
n/a
Revenue growth, year on year
latest reported quarter
+13.4%
Below the 52-week high
from the highest close of the year
-9.7%
1 week
−0.36%
1 month
−4.83%
3 months
+11.72%
6 months
+22.96%
1 year
+7.72%
The read
written from the numbers on this page
The evidence leans constructive6 supporting, 2 against, 0 worth knowing
Supporting
trading 11% above its 200-day average
up 8% over twelve months
matches falling on heavy volume, which has beaten the market by +1.45 points over 20 sessions across 11,619 past signals
4 of the scans it matches have a positive measured record
5 independent kinds of evidence agree today, which is uncommon
revenue grew 13% year on year in the quarter ending 30 June 2026
Against
net margin has narrowed from 3.2% to 2.4% across four quarters
priced at 315× earnings against an industry median of 45× — 604% above its peers
Worth knowing
nothing the data supports either way
What would change this read: a close below 629, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working5
Net profit rose 175.3% year on year, from Rs 6 cr to Rs 16 cr.
+175.3%Rs 6 crRs 16 cr
Profit grew faster than revenue, +175.3% against +13.4%.
+175.3%+13.4%
Revenue rose 13.4% year on year, from Rs 613 cr to Rs 695 cr.
+13.4%Rs 613 crRs 695 cr
Trading 11.4% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.
+11.4%
4 different kinds of evidence point at it tonight, not 4 versions of the same one.
4 families
Needs watching1
A warning rule fires on it tonight: falling on heavy volume.
Falling on heavy volume
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 3 of these 3 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
6 of 47 matched on 10 Sep
HCG matches 6 of the 47 scans today, across 5 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
HCG trades at 315× trailing earnings, above its median of 222× over this window — 42% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202) · AGM / EGM filings were typically +0.17pt vs the market over the next 5 sessions (n=8,423) · Results filings were typically -0.51pt vs the market over the next 5 sessions (n=7,726)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 13% against the same quarter a year earlier
profit rose 175% year on year
net margin widened from 0.6% to 2.4%
revenue rose in 3 of the last 4 quarters
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
695
24
16
0.92
2.4%
Q4 FY26
31 Mar · consolidated
652
1
4
0.15
0.6%
Q3 FY26
31 Dec · consolidated
633
-6
-8
—
-1.2%
Q2 FY26
30 Sep · consolidated
647
20
21
1.16
3.2%
Q1 FY26
30 Jun · consolidated
613
11
6
0.34
1.0%
Q4 FY25
31 Mar · consolidated
585
14
7
0.53
1.2%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+1.8%
Versus 200-day average+11.4%
Below 52-week high-9.7%
Above 52-week low+34.3%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)42.6
Higher closes in last 52 of 5
Six-month return+22.96%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.83%
Volume versus 20-day1.5x
Median daily turnoverRs 8.8 cr
Peers
Healthcare · 68 classified companies
HCG trades at 314.6× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — more expensive than them, by 604%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.